CAJ | 학술논문

系统性红斑狼疮（ systemic lupus erythematosus，SLE）是多系统损害的自身免疫性疾病，糖皮质激素和免疫抑制剂是治疗的主要药物。 SLE的骨损害包括骨量减少、骨质疏松（ osteoporosis， OP）、无菌性骨坏死和骨折，随着SLE生存期的延长，心血管并发症和OP成为影响患者生活质量和生存的主要因素，同时OP对于心血管的发病也有促进作用，是目前备受关注的并发症。 OP是一种以骨量减少和骨组织的细微结构破坏为特征的全身性疾病。关于SLE的骨质疏松也存在不少争议，主要集中在OP的发病率和骨质疏松与激素治疗关系两个方面。就OP发病率来讲，不同的研究得出的结论不同。 SLE的骨质疏松涉及多种机制包括炎性因素、免疫介导的因素、固有因素、代谢因素、药物因素和疾病本身的因素。 SLE相关的骨质疏松的治疗首先是治疗原发病，此外健康的生活方式包括钙剂和维生素D的补充也非常重要，对诊断骨质疏松的SLE 患者应及时给予双膦酸盐治疗。
계통성홍반랑창（ systemic lupus erythematosus，SLE）시다계통손해적자신면역성질병，당피질격소화면역억제제시치료적주요약물。 SLE적골손해포괄골량감소、골질소송（ osteoporosis， OP）、무균성골배사화골절，수착SLE생존기적연장，심혈관병발증화OP성위영향환자생활질량화생존적주요인소，동시OP대우심혈관적발병야유촉진작용，시목전비수관주적병발증。 OP시일충이골량감소화골조직적세미결구파배위특정적전신성질병。관우SLE적골질소송야존재불소쟁의，주요집중재OP적발병솔화골질소송여격소치료관계량개방면。취OP발병솔래강，불동적연구득출적결론불동。 SLE적골질소송섭급다충궤제포괄염성인소、면역개도적인소、고유인소、대사인소、약물인소화질병본신적인소。 SLE상관적골질소송적치료수선시치료원발병，차외건강적생활방식포괄개제화유생소D적보충야비상중요，대진단골질소송적SLE 환자응급시급여쌍련산염치료。
Systemic lupus erythematosus ( SLE) is an autoimmune disease involving multisystem.Glucocorticoids and immune-suppressors are main drugs for the treatment. The bone damage of SLE includes osteopenia, osteoporosis ( OP ) , aseptic osteonecrosis, and fractures.In recent years the survival of patients with SLE has increased markedly, and the complications of cardiovascular disease and OP become major factors affecting quality of life and death of the patients.OP can promote the onset of cardio-vascular disease, and it is the complication that we pay attention to.OP is a systemic disease characterized by bone loss and disruption of the microstructure.There are some debates about OP in SLE, mainly focusing on the incidence of OP and the relationship between OP and steroid treatment.For the incidence of OP, the conclusion is different from different study.The pathogenesis of OP in SLE includes chronic inflammation, immunological factors, traditional factors, metabolism factors, drug factors, and disease itself.Optimal treatment of the underlying SLE is the first step toward prevention of OP and fractures.Apart from that, a healthy lifestyle is important such as calcium and vitamin D supplementation.Bisphosphonates should be timely given for the SLE patients with osteoporosis.